ABSTRACT: Cardiac amyloidosis (CA) is a progressive and life-threatening manifestation of systemic amyloidosis characterized by extracellular deposition of insoluble amyloid fibrils in the myocardium.

ABSTRACT: Cardiac amyloidosis (CA) is a progressive and life-threatening manifestation of systemic amyloidosis characterized by extracellular deposition of insoluble amyloid fibrils in the myocardium.

Nonspecific symptoms and other diagnostic challenges lead to underdiagnosis of cardiac amyloidosis (CA). Artificial intelligence (AI) could help address these challenges, but a summary of the ...

The demographics of patients with transthyretin amyloidosis with cardiomyopathy have evolved over the past decade, mostly driven by improved awareness of the disease among clinicians, noninvasive ...

People with transthyretin cardiac amyloidosis (ATTR-CA ... previously been observed in 8-16% of those referred for cardiac MRI or transcatheter aortic valve replacement for AS.

Journal of Nuclear Medicine Technology April 2025, jnmt.124.269395; DOI: https://doi.org/10.2967/jnmt.124.269395 ...

8 had systemic amyloidosis but no cardiac involvement, and 17 had no evidence of systemic amyloidosis). 124 I-evuzamitide PET/MRI demonstrated 100% sensitivity and specificity in detecting cardiac ...

An interventricular septum brightness index from the apical 4-chamber view of the heart may identify subtle calcifications in the septum and help differentiate between transthyretin-mediated amyloid ...

Vutrisiran improved all-cause mortality and recurrent CV independent of disease severity in cardiac amyloidosis. Regardless of cutoffs, vutrisiran also improved various health and quality of life ...

Northeastern Health System has announced the launch of its Cardiac MRI service, aimed at improving diagnostic accuracy and advancing heart health care. This cutting-edge technology offers a ...

Lowering levels of circulating transthyretin with vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) decreased their risk for mortality and cardiovascular events ...